Travere Therapeutics (TVTX) said Tuesday that it has completed a meeting with the US Food and Drug Administration and plans to submit a supplemental New Drug Application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.
The application is based on the drug's mid-stage and late-stage studies and is expected to be submitted late in Q1, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.